Immunotherapy is one of the most exciting and dynamic fields in biopharma today. While the field itself is not new, checkpoint inhibitors have provided unparalleled breadth of clinical benefit across tumor types and CAR-T therapies have demonstrated deep responses in patients who previously failed multiple lines of therapy.

Despite this breakthrough clinical benefit, the field presents meaningful challenges to all healthcare stakeholders and the WISH Immunotherapy report will focus on the range of immunotherapies in development and available to patients, those challenges faced by innovators, patients, providers, and healthcare systems and how governments and policymakers can address them.